Vanderbilt Journal of Entertainment & Technology Law
Volume 19
Issue 1 Issue 1 - Fall 2016

Article 6

2016

Just What the Doctor Ordered: Protecting Privacy Without
Impeding Development of Digital Pills
Amelia R. Montgomery

Follow this and additional works at: https://scholarship.law.vanderbilt.edu/jetlaw
Part of the Computer Law Commons, and the Privacy Law Commons

Recommended Citation
Amelia R. Montgomery, Just What the Doctor Ordered: Protecting Privacy Without Impeding Development
of Digital Pills, 19 Vanderbilt Journal of Entertainment and Technology Law 147 (2020)
Available at: https://scholarship.law.vanderbilt.edu/jetlaw/vol19/iss1/6

This Note is brought to you for free and open access by Scholarship@Vanderbilt Law. It has been accepted for
inclusion in Vanderbilt Journal of Entertainment & Technology Law by an authorized editor of
Scholarship@Vanderbilt Law. For more information, please contact mark.j.williams@vanderbilt.edu.

Just What the Doctor Ordered:
Protecting Privacy Without Impeding
Development of Digital Pills
ABSTRACT

Using technology, humans are receiving more and more
information about the world around them via the Internet of Things,
and the next area of connection will be the inside of the human body.
Several forms of "digitalpills"thatsend informationfrom places like the
human digestive tract or bloodstream are being developed, with a few
already in use. These pills could stand to provide information that could
drastically improve the lives of many people, but they also have privacy
and data security implications that could put consumers at great risk.
This Note analyzes these risks and suggests that short-term
improvements in warning and obtaining consent from consumers be
implemented, while lawmakers carefully consider use constraints in
order to both protect consumers and allow the development of what could
be a highly beneficial form of technology.
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Experts estimate that in about ten years, up to one-third of
Americans will be living with either a temporary or permanent device
inside their bodies.' Humans have connected many of the objects they
use in everyday life-from phones and cars to coffee makers and
washing machines-to the Internet. This connectivity is known as the
Internet of Things. 2 Connecting the human body to the Internet is the
next logical frontier. Embedding technology into the human body
makes sense given that mHealth, which refers to the use of mobile
devices to support medical practice, is an area that is exploding in
popularity.3 These devices may come in many forms, but one form of
internal device already taking shape is the digital pill. While the
potential benefits are numerous, many skeptics cite serious risks to
privacy that must be addressed.
There are already various pills in use and development that
utilize technology to provide humans with information about what is
going on inside of them. One example is the SmartPill, which measures
pressure, pH levels, and temperature as it moves through patients'
bodies to measure motility. 4

American doctors are also using the

PillCam, a pill the size of a vitamin that contains small cameras and
moves through the digestive tract in only a couple of hours, capturing
images and transmitting them to an external data recorder, which
allows patients to forego invasive, uncomfortable procedures.' By
Scott R. Peppet, Regulating the Internet of Things: First Steps Toward Managing
1.
Discrimination, Privacy, Security, and Consent, 93 TEX. L. REV. 85, 104 (2014) (citing Cadie
Thompson, The FutureofMedicine Means PartHuman, Part Computer, CNBC (Dec. 24, 2013, 8:00
AM), http://cnbe.com/id/101293979 [https://perma.cc/5XZK-5UF4]).
2.
Jacob Morgan, A Simple Explanation of the 'Internet of Things,' FORBES (May 13,
2014), http://www.forbes.com/sites/jacobmorgan/2014/05/13/simple-explanation-internet-thingsthat-anyone-can-understand/#2dead45b6828.
3 WORLD HEALTH ORG., mHealth: New Horizons for Health Through Mobile
3.
Technologies,

in

GLOBAL

OBSERVATORY

FOR

EHEALTH

SERIES,

at

6

(2011),

http://www.who.int/goe/publications/goe-mhealth-web.pdf [https://perma.cc/C7ZN-SLSQ].
4.
Peppet, supra note 1, at 103 (citing Motility Monitoring, GIVEN IMAGING,
http://givenimaging.com/en-us/Innovative-Solutions/Motility/SmartPill/Pages/default.aspx
[https://perma.cc/G2RX-QS53]).
PillCam Capsule Endoscopy, GIVEN IMAGING, http://www.givenimaging.com/en5.
[https://perma.cc/832Y-M3G8]
int/Innovative-Solutions/Capsule-Endoscopy/Pages/default.aspx
(last visited Oct. 20, 2016); Adam D. Thierer, The Internet of Things and Wearable Technology:
Addressing Privacy and Security Concerns Without DerailingInnovation, 21 RICH. J.L. & TECH. 6,
32 (2015).
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making colon cancer screenings easier and more effective, this
technology could also make them more prevalent.6 Finally, a digital pill
that prevents drunk driving is also being developed.7 The pill would
place a microchip into the bloodstream of the consumer that measures
blood alcohol content when the person is in his car.8 If the blood alcohol
content is too high, the microchip will send a signal to the car, shutting
it off.9 If successfully implemented, this drug could prevent thousands
of
deaths
that
occur
each
year
due
to
alcohol-impaired driving and could save up to $49 billion. 10
Digital pills that combine ingestible microchip sensors with
pharmaceuticals that are already in use have great potential for
widespread adoption and high impact." These drugs can operate in a
number of ways. They can control and monitor the release of the active
pharmaceutical ingredients after digestion. 12 They can record whether,
when, where, and in what quantity the drug is released, as well as
information about the physical state of the person taking the drug, such
as temperature, activity level, heart rate, and respiration. 13 They also
transmit signals and information about the patient to devices such as
mobile phones, tablets and computers belonging to the patient, the
patient's caregivers, or the patient's doctor.1 4
One company, Proteus Digital Health, is endeavoring to develop
a digital pill that will measure and improve medication adherence and
generally improve health outcomes for those prescribed long-term
medications to treat chronic diseases. 15 An estimated 50% of patients

6.

Thierer, supra note 5, at 32 (citing Joseph Walker, New Ways to Screen for Colon

Cancer, WALL ST. J. (June 8, 2014, 4:54 PM), http://online.wsj.com/articles/new-ways-to-screen-forcolon-cancer-1402063124 [https://perma.cc/TZY5-Z8CV]).
7.
Biz Carson, Jawbone's CEO Sees a Future Where Tiny Sensors Travel in Your Blood,
BUS. INSIDER

(Oct.

7, 2015,

7:48 PM), http://www.businessinsider.com/jawbone-ceo-hosain-

rahman-imagines-bloodstream-wearables-2015-10
[https://perma.cc/66HM-XCMKQ];
Jason
Cipriani, Jawbone Is Building a Health Tracker You Can Swallow, FORTUNE (Oct. 8, 2015, 5:15
PM), http://fortune.com/2015/10/08/jawbone-ingestible-health-tracker/
[https://perma.cc/Z6QXMDHV].
8.
Carson, supranote 7.
9.
Id.
10.

Impaired Driving: Get the Facts, CTRS. FOR DISEASE CONTROL & PREVENTION (Nov.

24, 2015), http://www.cdc.gov/motorvehiclesafety/impaired driving/impaired-dry factsheet.html
[https://perma.cc/T9AZ-N9KZ]; NHTSA, Alcohol-Impaired Driving, U.S. DEP'T OF TRANSP. (Dec.
2014), http://www-nrd.nhtsa.dot.gov/Pubs/812102.pdf [https://perma.cc/84WL-Z7LV].
11.
Matthew Avery & Dan Liu, Bringing Smart Pills to Market: FDA Regulation of
Ingestible Drug/Device Combination Products, 66 FOOD & DRUG L.J. 329, 330-32 (2011).
12.
Id. at 331.
13.
Id. at 331-32.
14.
Id. at 332.
15.
US FDA Accepts Digital Medicine Drug Application for Otsuka and Proteus Digital
Health, BUS. WIRE (Sept. 10, 2015, 9:00 AM), http://www.businesswire.com/news
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with chronic diseases in developed countries do not take their
medication as prescribed. 16 This can cause relapse and recurrence of
chronic diseases and results in an estimated $100-$300 billion in
avoidable health care costs, both direct and indirect.1 7 If successfully
implemented, this new drug could significantly impact the way
medication adherence is measured and, in doing so, could revolutionize
the way that chronic disease treatment is tailored to individuals. The
ability to measure medication adherence would allow health care
professionals to more effectively tailor treatment of chronic diseases to
individual patients, which could not only lead to better health outcomes,
but also save billions of dollars in health care costs.1 8
Despite Proteus's potential for positive impact, there are
significant drawbacks and possible barriers to its success. Privacy
concerns already exist with regard to mHealth and the Internet of
Things.1 9 Therefore, these concerns will extend to the Proteus digital
pill, which, as a digital ingestible sensor that sends daily information
to a software application for mobile devices, qualifies as both. The
concerns include a lack of certainty over which privacy laws and
regulations apply to data created and transmitted using digital sensors,
the insufficiency of the approaches to privacy preservation taken by
current privacy laws, and the inherent security weaknesses of sensor
devices. It is possible that, in response to these potential issues, the
digital pill could fail before implementation as a result of precautionary
overregulation of the use of information collected by the digital pill.
This Note addresses the privacy and data security issues that
could stand in the way of the success of the Proteus digital pill and, in
doing so, addresses how these issues could prevent implementation of
ingestible sensors generally. Part I describes the development and
potential benefits of the Proteus digital pill, as well as potentially
applicable privacy and data security laws and regulations. Part II
analyzes the application and adequacy of these laws and regulations in
light of the actual privacy and security threats posed by the digital pill
and the levels of privacy and data security desired by consumers. Part
III offers a solution that would not only allow the digital pill to be
implemented successfully to treat chronic diseases, but also provide

/home/20150910005497/en/U.S.-FDA-Accepts-Digital-Medicine-Drug-Application
[https://perma.cc/B692-58Z9].
16.
Id.
17.
Id.
18.
Id.
See Anne M. Helm & Daniel Georgatos, Privacy and mHealth: How Mobile Health
19.
"Apps" Fit into a Privacy FrameworkNot Limited to HIPAA, 64 SYRACUSE L. REV. 131, 158 (2014);
Peppet, supra note 1, at 88-89, 129-33; see also WORLD HEALTH ORG., supra note 3, at 6.
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consumers and health care providers with sufficient privacy and data
security protection.
I. BACKGROUND
A. The Proteus Digital Pill
For several years, Proteus has been pioneering digital pill
technology by developing its digital health feedback system, which
consists of an ingestible sensor and external patch that collect and send
information and a software platform that receives and displays that
information. Proteus has been seeking regulatory approval of these
projects and partnering with companies that are interested in using
Proteus's ingestible sensor to improve health care delivery. The system
is intended to improve treatment by creating an "integrated approach
to patient-centric, anywhere, anytime mobile health products" in a
number of areas of personal health, including cardiovascular disease;
psychiatric, metabolic, and neurologic disorders; organ transplantation;
and infectious disease. 20
1. Development of the Ingestible Sensor
The Proteus sensor is one millimeter long and one-third of a
millimeter thick-the size of a grain of sand. 2 1 It is made of silicon,
copper, and magnesium that form a circuit with human stomach acid to
power the microchip. 22 The microchip sends a signal to a patch worn on
the abdomen skin that records and time-stamps the information. 23 The
patch also collects other patient metrics, including whether the patient
is resting, the angle of the patient's body, and the patient's patterns of
activity. 24
From the patch, information can be transmitted to the patient's
smartphone or other Bluetooth-enabled device and then on to the

20.
Press Release, Proteus Digital Health, Proteus Digital Health Announces FDA
Clearance of Wireless Personal Health Monitor (Apr. 21, 2010), http://www.proteus.com/pressreleases/proteus-announces-fda-clearance-of-wireless-personal-health-monitor/
[https://perma.cc/DL6E-QXYS] [hereinafter Press Release, Proteus Digital Health Apr. 21, 2010].
21.
Russell Brandom, The FrighteningPromise of Self-Tracking Pills, THE VERGE (Oct.
7, 2015, 11:16 AM), http://www.theverge.com/2015/10/7/946612 1/proteus-digital-pill-trackingprivacy-quantified-self [https://perma.cc/XK8B-P988].
22.
Id.
23.
Id.
24.
See Press Release, Proteus Digital Health, Proteus Digital Health Announces FDA
Clearance of Ingestible Sensor (July 30, 2012), http://www.proteus.com/press-releases/proteusdigital-health-announces-fda-clearance-of-ingestible-sensor-2/
[https://perma.cc/2UM3-96UE]
[hereinafter Press Release, Proteus Digital Health July 30, 2012].
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patient's physician or caregiver, if the patient has consented. 25 The
patient may view the information from the patch and sensor using a
software application ("app") on her mobile phone or other device, and
26
the physicians or caregivers may view the data via web portals.
27
Proteus has characterized these apps and web portals as "secure."
In August 2010, Proteus Biomedical Inc. announced that it
would affix the CE Mark to an ingestible sensor and monitor system,
signaling Proteus's assertion that the system met European Union
28
In
consumer and health requirements and could be marketed there.
the United States, the Proteus Feedback System, which is solely an
ingestible sensor independent of any other pharmaceutical drug, was
approved by the United States Food and Drug Administration (FDA)
for marketing as a medical device in July 2012.29 In July 2015, the FDA
expanded the Indications for Use statement for Proteus's ingestible
sensors, allowing the device to be used to measure medication
an
with
device
only
it
the
rendering
and
adherence
30
this
made
The FDA
FDA-approved claim for such measurement.
decision because the ingestible sensor records a quantifiable event:
actual intake time. 31
2. How the Ingestible Sensor Will Be Used
To be effective, the ingestible sensor and accompanying system
must be combined with pharmaceutical products for which they can
measure adherence. In January 2010, Proteus Biomedical and Novartis
entered into an exclusive worldwide license and collaboration
agreement to create pharmaceutical products that will utilize Proteus's
sensor technology in the fields of organ transplantation, cardiovascular

25.
Id.
26.
Id.
See Ms. Smith, FDA Accepts Application for Micro-ChippedPill that Tells Doc if You
27.
Took Meds, NETWORK WORLD: PRIVACY & SECURITY FANATIC (Sept. 14, 2015, 7:12 AM),
http://www.networkworld.com/article/2983387/security/fda-accepts-application-for-microchipped-pill-that-tells-doc-if-you-took-meds.html [https://perma.cc/3UTK-QKRA].
Press Release, Proteus Digital Health, Proteus Biomedical Announces European CE
28.
Mark
Approval
of Ingestible
Sensor
and
Monitor
System
(Aug.
13,
2010),
http://www.proteus.com/press-releases/proteus-biomedical-announces-european-ce-mark-

[hereinafter
[https://perma.cc/ET2J-EGED]
approval-of-ingestible-sensor-and-monitor-system/
Press Release, Proteus Digital Health Aug. 13, 2010].
Peppet, supra note 1, at 103-04; see also Press Release, Proteus Digital Health July
29.
30, 2012, supra note 24.
Press Release, Proteus Digital Health, First Medical Device Cleared by FDA with
30.
Adherence Claim (July 2, 2015), http://www.proteus.com/press-releases/first-medical-devicecleared-by-fda-with-adherence-claim/ [https://perma.ce/F4QP-4G3N] [hereinafter Press Release,
Proteus Digital Health July 2, 2015].
31.
Id.
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health, and oncology. 32 Proteus has also indicated to the European
Medicines Agency (EMA) that it intends to use the digital pill to monitor
medication adherence in patients with Type 2 diabetes, hypertension,
Alzheimer's disease and hepatitis C, as well as patients who have been
recently discharged from a hospital. 33 In April 2016, at the annual
conference of the American College of Cardiology, Proteus shared that
in a study of its digital feedback system, more than 84% of patients with
uncontrolled hypertension and Type 2 diabetes using the combination
of the digital sensor, the patch, and the app were able to reach their
blood pressure targets, compared with only 33% of patients receiving
usual care. 3 4 The first use of the digital feedback system outside of
clinical settings in the United States will be by Barton Health, a health
system in Lake Tahoe, California. 35 Barton will combine the sensor
with generic medications for patients with uncontrolled and co-morbid
hypertension.
Proteus is also seeking approval of a digital pill that will
measure medication adherence in psychiatric patients. In July 2012,
Proteus Digital Health and Otsuka Pharmaceutical Co. announced a
license and collaboration agreement to develop medicines based on
Otsuka's pharmaceutical products and Proteus's digital health
feedback system in two therapeutic areas with high unmet medical
needs. 36 Otsuka produces ABILFY, a drug used to treat schizophrenia,
manic or mixed episodes occurring with bipolar I disorder, major

32.

Press Release, Proteus Digital Health, Proteus Biomedical Announces License and

Collaboration
Agreement
for
Sensor-Based
Pharmaceuticals
(Jan.
12,
2010),
http://www.proteus.com/press-releases/proteus-biomedical-announces-license-and-collaboration
-agreement-for-sensor-based-pharmaceuticals/ [https://perma.cc/6YJ7-DNMS] [hereinafter Press
Release, Proteus Digital Health Jan. 12, 2010].
33.
Draft Qualification Opinion, EUROPEAN MEDICINES AGENCY 25 (Aug. 7, 2015),
http://www.ema.europa.eu/docs/enGB/documentlibrary/Regulatory-and-procedural-guideline

/2015/09/WC500193612.pdf [https://perma.cc/ZAA6-GTYL].
34.
Stephanie Baum, Proteus Digital Health Smart Pill Study Shows Significant
Reduction
in
BP
Levels,
MEDCITY
NEWS
(Apr.
4,
2016,
4:41
PM),
http://medcitynews.com/2016/04/proteus-digital-health?rf=1 [https://perma.cc/8TAZ-WAAD].
35.
Jonah Comstock, California Hospital Becomes First in US to Prescribe Ingestible
Sensors from Proteus, MOBIHEALTHNEWS (Jan. 11, 2016), http://mobihealthnews.com/content

/california-hospital-becomes-first-us-prescribe-ingestible-sensors-proteus
[https://perma.cc/9TSR
-5M98].
36.
Press Release, Proteus Digital Health, Proteus Digital Health, Inc. and Otsuka
Pharmaceutical Co., Ltd. Announce Worldwide Agreement to Develop Novel Digital Health
Products (July 5, 2012), http://www.proteus.com/press-releases/proteus-digital-health-inc-andotsuka-pharmaceutical-co-ltd-announce-worldwide-agreement-to-develop-novel-digital-health
-products-2/ [https://perma.cc/B4V-RSC8] [hereinafter Press Release, Proteus Digital Health
July 5, 2012].
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depressive disorder, irritability associated with autistic disorder, and
Tourette's Syndrome. 37
On September 8, 2015, the FDA deemed the New Drug
Application for a tablet containing ABILIFY embedded with a Proteus
ingestible sensor to be sufficiently complete for substantive review.38
Proteus and Otsuka are the first to submit an application for
FDA-approved medication that contains an ingestible sensor. 39 In April
2016, the FDA issued a Complete Response Letter requesting
additional information about the product's performance and any
use-related risks that patients taking it might face. 40 Otsuka's
executive vice president and chief strategy officer, Robert McQuade,
stated that Otsuka and Proteus would work to provide the information
the FDA has requested. 4 1
B. Benefits of the ProteusDigital Pill
There are many benefits to be realized from the use of digital
pills. Digital pills will alert doctors to whether a patient is taking his
medication, when it is being taken, the patient's physical status at the
time the medication is taken, and how the medication works in the
patient's body. 4 2 The doctors and caregivers of a patient can thus both
be alerted if that patient stops taking his medication and have access
to general information about the patient's situation at the time he
stopped taking the medication. 43 This is important for two reasons.
First, doctors administering medications to patients with
chronic illnesses may be able to devise more effective treatment plans
that are tailored to individual patients' needs after observing the
medication adherence habits of the patients. 44 For example, patients
are 3.5 times more likely not to take medications as prescribed if they

Otsuka Pharm. Co., ABILIFY Medication Guide (Aug. 2016), http://www.otsuka37.
us.com/products/Documents/Abilify.Medguide.pdf [https://perma.ccUM3W-HET6].
Press Release, Proteus Digital Health, U.S. FDA Accepts First Digital Medicine New
38.
10,
2015),
(Sept.
Digital Health
for
Otsuka and Proteus
Drug
Application
http://www.proteus.com/press-releases/u-s-fda-accepts-first-digital-medicine-new-drug
[https://perma.cc/P7NF-TKL3] [hereinafter
-application-for-otsuka-and-proteus-digital-health/
Press Release, Proteus Digital Health Sept. 10, 2015].
39.
Id.
40.
Dominic Tyler, FDA Knocks-Back Otsuka's DigitalPill Plans, PMLIVE (May 6, 2016),
http://www.pmlive.com/blogs/digital-intelligence/archive/2016/may/fda-knocks
-back-otsukas digitalpill-plans_1017143 [https://perma.cc/3Z69-GYPW].
41.
Id.
42.
Id.
43.
Id.
44.
Press Release, Proteus Digital Health July 5, 2012, supra note 36.
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have reported having side effects from the medication. 45 If a doctor is
alerted by the Proteus digital feedback system that the patient is not
taking his medication, the doctor may be able to contact the patient,
learn more quickly about the side effects the patient was experiencing,
and adjust the patient's prescriptions so that he is more likely to take
the medication. 46 Also, physicians may make costly and unnecessary
changes in treatment when the physician is unaware that a patient who
is not seeing results is actually just non-adherent. 4 7
Second, medication non-adherence can negatively affect health
outcomes.48 For example, patients taking ABILIFY for schizophrenia
or bipolar I disorder could be susceptible to manic and schizophrenic
episodes if their medications are discontinued without the direction of
a doctor. 49 The Proteus digital feedback system could be particularly
helpful for these patients because they are often reluctant to let anyone
know that they have stopped taking their medication.5 0 For patients
with
high
blood
pressure,
it
has
been
shown
that
non-adherence can result in a 42% higher chance of chronic heart
failure.5 1 Diabetics who fail to adhere to their diabetes medications are
2.5 times more likely to be hospitalized than diabetics who regularly
take their medications. 52
If successfully implemented in treating patients with chronic
diseases, the digital pill could have a significant economic impact on the
health care industry by encouraging better adherence to prescription
medications. 53 Medication non-adherence results in an estimated
$100-$300 billion in avoidable direct and indirect health care costs,
which represents 3% to 10% of total health care costs in the United
States. 54 Nearly one in two Americans have chronic diseases, such as
45.
See Improving Prescription Medication Adherence Is Key to Better Health Care,
PHRMA (Nov. 18, 2014), http://www.phrma.org/publications/improving-prescription-medicine
-adherence-is-key-to-better-health-care [https://perma.cc/ES2X-F5CC][hereinafter PHRMA].
46.
Id.
47.
Comstock, supra note 35.
48.
Aurel 0. luga & Maura J. McGuire, Adherence and Health Care Costs, 7 RISK MGMT.
&

HEALTHCARE

POL'Y

35

(2014),

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934668/

[https://perma.cclY8MT-DRAS].
49.
Jonah Comstock, Proteus, Otsuka Submit First Commercial Drug with Built-in
Sensor to FDA, MOBIHEALTHNEWS (July 2, 2015), http://mobihealthnews.com/46680/proteus
-otsuka-submit-first-commercial-drug-with-built-in-sensor-to-fda [https://perma.cc/37DG-89E3].
50.
Jonah Comstock, FDA Expands Proteus Digital Health's Clearance to Include
Measuring
Medication
Adherence,
MOBIHEALTHNEWS
(July
2,
2015),
http://mobihealthnews.com/44949/fda-expands-proteus-digital-healths-clearance-to-include
-measuring-medication-adherence/ [https://perma.cc/JX9C-A8JM].
51.
See PHRMA, supra note 45.
52.
Id.
53.
Press Release, Proteus Digital Health July 5, 2012, supra note 36.
54.
Iuga & McGuire, supra note 48.
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cardiovascular disease, asthma, depression, cancer, or diabetes.5 5
Patients with these illnesses who do not adhere to their medications
have higher health care costs than patients who do adhere to
medications, resulting largely from hospital admissions, emergency
room visits, and other inpatient costs. 56

Additionally, when these

patients do not take their medications, insurance companies are
wasting money on the unused drugs.5 7
Another benefit of the Proteus digital pill is that it can be used
to accelerate, improve the accuracy of, and reduce the costs of clinical
trials.5 8 It is crucial to the success of a clinical trial that the
participating patients adhere to the treatment being tested and
evaluated.5 9 Current methods for measuring adherence, including pill
counts and patient questionnaires, are expensive, time-consuming, and
imprecise. 60 Unsuccessful clinical trials can also result from an
inability to determine inappropriate dosages; if the participating
patient is not taking the medication, the researchers conducting the
study will not know whether the dosage needs to be adjusted. 6 1
Proteus intended the digital feedback platform to address both
of these issues in clinical trials, in addition to its uses in treating
patients. 62 In January 2015, Proteus integrated its digital feedback
platform with Oracle Health Sciences Inform electronic data capture
platform to create a cloud service that enables clinical trial sponsors to
capture precise data about medication adherence in real time. 63 This
move, as well as Proteus's request that the European Medicines Agency
approve the use of its digital platform as a method for measuring
adherence and physiological and behavioral parameters in clinical

Id.; see also PHRMA, supra note 45.
55.
See PHRMA, supra note 45.
56.
Robert Glatter, MD, Proteus Digital Health and Otsuka Seek FDA Approval for
57.
AM),
8:09
2015,
14,
(Sept.
FORBES
Pill,
Digital
First
World's
http://www.forbes.com/sites/robertglatter/2015/09/14/proteus-digital-health-and-otsuka-seek-fda
-approval-for-worlds-first-digital-medicine/#25adffd94b5c.
See Comstock, supra note 49; Press Release, Proteus Digital Health, Oracle and
58.
Proteus Integrate Proteus Digital Health Feedback System with Oracle Health Sciences InForm
to Help Increase Clinical Trial Accuracy (Jan. 12, 2015), http://www.proteus.com/press
-releases/oracle-and-proteus-integrate-proteus-digital-health-feedback-system-with-oracle-health
[https://perma.cc/3BND-WAMS]
-sciences-inform-to-help-increase-clinical-trial-accuracy/
[hereinafter Press Release, Proteus Digital Health Jan. 12, 2015].
Press Release, Proteus Digital Health Jan. 12, 2015, supra note 58.
59.
Id.
60.
Id.
61.
Press Release, Proteus Digital Health July 2, 2015, supra note 30.
62.
Press Release, Proteus Digital Health Jan. 12, 2015, supra note 58.
63.
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trials, demonstrates that Proteus is actively seeking to use its
technology to improve the efficiency and effectiveness of clinical trials. 64
C. Current Laws Applicable to Ingestible Sensors
1. Privacy Laws
Privacy law in the United States began with limited common law
torts designed to compensate victims actually injured by privacy
invasion and has morphed into a broader statutory scheme that seems
to recognize a right of privacy and is designed to prevent privacy
harms. 65 Congress's approach to reducing the risk of privacy harm has
been to categorize information according to its tendency to cause harm
if disclosed and to regulate data that are considered riskier than other
types of data. 66 The two types of data considered to be risky are
personal information that lawmakers believe can be used to directly
cause harm if disclosed and data that cannot be used to directly cause
harm but can be used to reidentify anonymized data.6 7 Because these
types of data are regulated, lawmakers have relied on anonymization
to protect consumer privacy.6 8 The idea is that consumers will be
protected against harmful uses of their personal information if
organizations that collect data promise only to share those data in ways
that are de-identified and anonymous. 69
The federal statute that regulates privacy in health information
is the Health Insurance Portability and Accountability Act (HIPAA).70
The HIPAA Privacy Rule was published in 2000 and expanded in 2009
by the Health Information Technology for Economic and Clinical Health
Act (HITECH).7 1
Both the HIPAA Privacy Rule and HITECH
mandated adoption of technology in health care and attempted to
address the issues that such adoption would bring about for the privacy
64.

Lisa Henderson, Proteus Seeks EMA Approval on Ingestible Sensor, APPLIED

CLINICAL TRIALS (Oct. 16, 2015), http://www.appliedclinicaltrialsonline.com/proteus-seeks-emaapproval-ingestible-sensor.

65.
See Paul Ohm, Broken Promises of Privacy: Responding to the SurprisingFailureof
Anonymization, 57 UCLA L. REV. 1701, 1732-34 (2010).
66.
See id. at 1734.
See id. at 1735.
67.
68.
See id. at 1736.
69.
See Peppet, supra note 1, at 129.
70.
See id. at 139, 154; see Rachel V. Rose, How Does HIPAA and the HITECHAct Impact
Medical Device and Pharma Companies?, BECKER'S HosP. REV. (Jan. 11, 2013),
http://www.beckershospitalreview.com/healthcare-information-technology/how-does-hipaa-andthe-hitech-act-impact-medical-device-and-pharma-companies.html
[https://perma.cc/PZA2Q2TF].
71.
See HIPAA Rules, HIPAA SURVIVAL GUIDE, http://www.hipaasurvivalguide.com
/hipaa-rules.php [https://perma.cc/HZ3V-LJG3] (last visited Oct. 26, 2016).
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of patient health information. 72 The HIPAA Privacy Rule applies to
covered entities, which are defined as health plans, health care
clearinghouses, health care providers, and their business associates
who transmit health information in electronic form in connection with
a transaction covered by the Privacy Rule. 7 3 A business associate is a
person or organization that is not part of a covered entity's workforce
that performs certain functions on behalf of or provides certain services
to covered entities when those functions or services involve the use or
disclosure of protected health information. 74 Business associates
include any persons that provide services for data transmission of
protected health information to a covered entity and requires access on
a routine basis to such protected health information.7 5
The Privacy Rule also only covers health information that
qualifies as protected health information (PHI), defined as "individually
identifiable health information that is: (i) transmitted by electronic
media; (ii) maintained in electronic media; or (iii) transmitted or
maintained in any other form or medium." 76 There are three elements
that information must satisfy to be considered "individually identifiable
health information."7 7 First, the information must be either "created or
received by a health care provider, health plan, employer, or health care
clearinghouse."7 8 Second, the information must relate to one of the
following: "the past, present, or future physical or mental health or
condition of an individual; the provision of health care to an individual;
or the past, present, or future payment for the provision of health care
to an individual."7 9 Finally, the information must either actually
identify the individual or reasonably could be used to identify the
individual.8 0
Health information that neither identifies nor provides a
reasonable basis to identify an individual is de-identified health
information (DHI).8 1 There are two standards under which the U.S.
Department of Health and Human Services (HHS) analyzes whether
information could reasonably be used to identify an individual. 82 First,
72.
See id.
45 C.F.R. § 160.103 (2014).
73.
Id.
74.
Id.
75.
76.
Id.
77.
Id.
78.
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79.
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Id.
80.
OFFICE FOR CIVIL RIGHTS, Summary of the HIPAA Privacy Rule 4, HHS.GOV (May
81.
2003), http://www.hhs.gov/sites/default/files/privacysummary.pdf [https://perma.ccVA3A-XJBN]
[hereinafter OCR, Summary].
Ohm, supranote 65, at 1737.
82.
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the statistical standard states that information is DHI if a statistician
or someone with "appropriate knowledge .

.

. and experience" decides

formally that the data are not individually identifiable. 83 Second, the
safe harbor standard allows information to become DHI if the covered
entity suppresses or generalizes eighteen enumerated identifiers,
including generalizing birth dates to years and ZIP codes to the initial
three digits of the code. 8 4 Information that qualifies as DHI can be used
and traded without restriction of any kind.85
The HIPAA Privacy Rule sets forth requirements that limit the
circumstances under which an individual's PHI may be used or
disclosed by covered entities. 86 There are specific circumstances under
which the Privacy Rule either permits or requires the disclosure or use
of PHI, and PHI may be used or disclosed when the individual has
authorized such use or disclosure in writing.8 7 For example, PHI may
be used or disclosed in the context of treatment, payment, research and
public health activities.8 8 Most state laws contrary to the HIPAA
Privacy Rule are preempted. 89
Section 13408 of the HITECH Act applies to organizations that
both transmit PHI to covered entities or their business associates and
require access to the PHI on a routine basis.9 0 These organizations may
include Health Information Exchange Organizations, Regional Health
Information Organizations, E-prescribing Gateways, or vendors that
contract with a covered entity to allow the covered entity to offer a
personal health record (PHR) to patients as part of its electronic health
record. 91 According to the American Health Industry Management
Association, a personal health record is "an electronic, universally
available, lifelong resource of health information needed by individuals
to make health decisions." 92 PHRs can be populated by patients or by
entities such as health care providers, insurers, and pharmacies. 93

83.
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85.
Id.
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OCR, Summary, supra note 81, at 1.
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Id. at 4.
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Id. at 4-8.
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Id. at 17.
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Health Information Technology for Economic and Clinical Health Act § 13408, 42
U.S.C. § 17938 (2010).
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Juliana Bell, Privacy at Risk: Patients Use New Web Products to Store and Share
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(2010
Update),
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(2010),
http://1ibrary.ahima.org
/xpedio/groups/public/documents/ahimalbokl048517.hcsp?dDocName=bokl_048517
[https://perma.cc/9B3U-XMVP].
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See id.
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Under the HITECH Act, these organizations are considered business
associates for purposes of HIPAA and must enter into Business
Associate Agreements with the covered entities to which they transmit
PHI. 94
Consumer protection laws like the Federal Trade Commission
Act (FTC Act) provide another method for protecting privacy.9 5 This act
is not specific to health information, but has been applied to mobile
apps. 96 The FTC Act gives the Federal Trade Commission (FTC) the
power to regulate marketing practices and deceptive advertisements.9 7
This has allowed the FTC to pursue cases against app developers who
engage in practices that are contrary to the privacy policies published
about the apps. 98 For example, the Path social networking app
automatically collected and stored information that was gathered from
app users' mobile devices, even if a user had declined to give the app
permission to do so. 99 The FTC sued Path's operators for this violation
of the FTC Act, as well as for making misrepresentations in its privacy
policy and collecting personal information from children without
parental consent; under its settlement with the FTC, Path had to pay
an $800,000 fine and institute a comprehensive privacy program that
included periodic privacy assessments.10 0
Another type of privacy law that has been suggested but not yet
widely implemented with respect to the Internet of Things is "use
constraints."1 0 1 Rather than relying on anonymization, use constraints
directly limit different parties' abilities to collect, store, and use specific
types of data. 102 An example of a use constraint that already exists is
some state legislatures' having passed laws limiting employers'
consideration of applicants' credit reports. 103
In the context of information privacy, use constraints could take
several forms. 104 They could limit cross-context use of information data
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[https://perma.cc/5UNS-HL9Y]).
See Peppet, supranote 1, at 150-57.
101.
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by Buying into the Internet of Things, 94 TEX. L. REV. 1023, 1052 (2016).
See Peppet, supranote 1, at 151-52.
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whereby, for example, employers, insurers, or other economic actors can
use data about an individual to draw inferences that allow them to
discriminate against these individuals on the basis of race, gender, age,
or economic status.10 5
Use constraints could also prevent forced
disclosure of specific information.10 6 For example, a handful of states
have passed laws that restrict insurance companies from requiring that
an insured disclose the data collected by the Event Data Recorder in the
insured's automobile.10 7
Some states have advocated for the
implementation of use constraints in the arena of Internet of Things
data, but currently few have enacted such laws and those that exist are
narrowly tailored.10 8
2. Data Security Laws
In the United States, there is no general federal data security
statute, and data security is regulated via the FTC Act and state data
breach notification laws. 109 Data security with regard to health
information is also regulated by the HIPAA Security Rule. 110 The FTC
Act gives the FTC the power to prevent people and entities from using
"unfair or deceptive acts or practices in or affecting commerce." 1 1' This
mandate has given rise to two types of enforcement cases: deception and
unfairness. 112 Deception cases arise when a company violates securityrelated statements it has previously made to consumers. 113 For
example,
the
FTC
brought
an
action
against
web-enabled camera manufacturer TRENDnet after a Houston couple's
baby monitor was hacked. 114 Even though TRENDnet had promised
customers that its cameras were secure, the male hacker was able to
shout expletives at the baby through the camera.11 5 This was the FTC's
first action against an Internet of Things manufacturer, and it resulted
in a consent order with TRENDnet requiring the implementation of a
rigorous security program to address risks and protect consumers'
information.1 16
105.
Id. at 151.
106.
Id. at 153.
107.
See id. at 154-55.
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109.
See id. at 136-37.
110.
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The other type of data security cases the FTC has brought are
unfairness cases.1 17 In order to declare an act or practice unfair, the
FTC must show that the act or practice is "likely to cause substantial
injury to consumers which is not reasonably avoidable by consumers
themselves and not outweighed by countervailing benefits to consumers
or to competition." 1 8 The FTC may also use public policy to support the
contention that a practice is unfair.1 19 In the health care industry,
HIPAA could serve as a sufficient public policy, making it easier for the
FTC to establish a case of unfair practice with regard to data security. 120
Even in contexts where there are no federal statutory requirements
about data security, the FTC has been able to successfully argue that it
has jurisdiction to bring an enforcement action over unfair data security
practices, suggesting that this jurisdiction is rather broad. 121
In addition to FTC regulation, forty-six states have data breach
notification statutes. 12 2 These statutes require notification when
security breaches result in the theft of records containing "personal
information"-a combination of an individual's first and last name and
either the individual's Social Security Number, driver's license number,
or bank or credit card account information. 123 While the majority of
states do not mention health information in their data security statutes,
eight states have specifically included it in their definitions of personal
information. 124 Arkansas, California, Missouri, and Puerto Rico include
"medical information." 12 5 Iowa, Nebraska, Texas, and Wisconsin
include a person's "unique biometric data." 126
Finally, in the health care industry, the HIPAA Security Rule
and the American Recovery and Reinvestment Act of 2009 ("Recovery
Act") regulate data security. 127 The Security Rule applies to the same
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entities and information as the HIPAA Privacy Rule, and it was
designed to be flexible and technologically neutral enough to apply to
new technology. 128 The rule requires that covered entities implement
administrative, physical, and technical safeguards that will achieve
four objectives: guarantee the confidentiality of PHI that a covered
entity creates, receives, or transmits; identify and protect against
reasonably anticipated security threats to PHI; protect against
reasonably anticipated impermissible uses or disclosures; and
guarantee compliance by the entity's workforce. 129
Further, HITECH requires entities covered by HIPAA to notify
both the affected individuals and HHS upon discovering that there has
been a breach of unsecured PHI. 130 HHS must post a list of covered
entities that have reported such breaches of PHI involving more than
500 individuals, and if over 500 residents of a state or jurisdiction have
been affected, the covered entity must alert the media in that state or
jurisdiction. 13 1 For vendors of personal health records, who may not be
covered by HIPAA, the Recovery Act requires that, following the
discovery of a security breach of PHR identifiable health information,
the vendor must notify each individual whose information was accessed
and the FTC. 132
II. ANALYSIS

A. Lack of Clarity over Applicable Privacy Laws
It is not clear which privacy laws will actually apply to digital
pills. The HIPAA Privacy Rule applies only to individually identifiable
health information that is stored or transmitted by "covered entities"
and their "business associates." 1 3 3 Covered entities are usually health
care providers, health insurers, or health care clearinghouses that
process billing information, not pharmaceutical companies. 134
Pharmaceutical companies can be considered "business associates" if
they perform "functions or activities on behalf of, or certain services for,
a covered entity that involve the use or disclosure of protected health
Which: Striking the Balance Between PrivacyProtection and the Flow of Health Care Information,
16 MICH. TELECOMM. & TECH. L. REV. 279, 304 (2010).
128.
See Helm & Georgatos, supra note 19, at 154-55.
129.
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131.
Breach Notification for Unsecured Protected Health Information, 74 Fed. Reg. 42,740
(proposed Aug. 24, 2009); Helm & Georgatos, supra note 19, at 153-56.
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American Recovery and Reinvestment Act of 2009, Pub. L. No. 111-5, § 13407, 123
Stat. 115, 269-70.
133.
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134.
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information."1 3 5 It is possible that Proteus could be seen as performing
functions, activities, or services for health care providers who receive
the information transmitted from the digital pill. If so, Proteus would
be required to enter into business associate contracts with each covered
entity for which it performs functions or activities-a cumbersome
practice that it seems unlikely a company would put itself in a position
to have to do. 136
On the other hand, Proteus may not actually be providing a
Proteus allows patients to access
service to covered entities.
Doctors only receive the
information transmitted by a pill.137
information if the patient allows the doctor to access a web portal. 138 It
is possible that Proteus would not be considered a business associate
subject to the HIPAA Rules because it is only providing a service to the
patient, not to a covered entity. 139 In fact, because patients can choose
to keep the information to themselves, the information sent from a
patient's digital pill could potentially never reach a covered entity at

all.
As Proteus is a vendor of PHRs that may be accessed by covered
entities, it is possible that Proteus could be covered by Section 13408 of
the HITECH Act. 140 It is more likely, though, that Proteus's provision
of PHRs will escape such regulation because Proteus will not be
contracting with health care providers to allow them to offer personal
health records to their patients. 14 1 Instead, Proteus will provide PHRs
to individual patients who may or may not choose to then share their
personal health records with their physicians, possibly not implicating
a covered entity at all. 14 2 Where an entity operates systems that
provide PHRs directly to consumers rather than handling the
information under the provisions of a business associate agreement
with a covered entity, many experts agree that there is a gap in HIPAA
coverage. 143 The Proteus digital pill could fall into that gap and,
consequently, the information collected by Proteus will not be subject to
HIPAA's rules regarding handling, storing, and transmitting of
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135.
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information. Instead, those seeking protection or redress for privacy
and data security-related issues will have to look to the myriad varying
state regulations concerning these topics, the "deception" and
"unfairness" prongs of the FTC Act, and the data breach requirements
for PHR vendors under the Recovery Act.
B. Shortcomings of Anonymization
Even if HIPAA or a more stringent state privacy statute or
regulation does apply to Proteus, the personal information of digital pill
consumers could be at risk. According to Paul Ohm, "almost every
single privacy statute and regulation ever written in the U.S. and the
EU
embraces-implicitly
or
explicitly,
pervasively
or
only
incidentally-the assumption that anonymization protects privacy." 144
Privacy and data security statutes and regulations frequently offer safe
harbors to entities that anonymize their data. 145 For example, under
HIPAA, there are no restrictions on the use and disclosure of DHI. 146
Now, due to advances in computer science, it is possible. to
reidentify
databases
that were
supposedly
protected using
anonymization, and this fact weakens the protections that these laws
and regulations provide to consumers and their information. 147 One
study found that 87% of Americans could be uniquely identified using
the combination of their ZIP code, birth date, and sex. 148
In 2006, it was discovered that users could be easily identified
in an anonymized database released by Netflix. 149 Netflix had released
one hundred million records to reveal how its users had rated movies
from December 1999 to December 2005.150 Although Netflix had
removed identifying information, those with access to the database
could see the movies each user rated, the dates they rated them, and
the rating they assigned. 15 1 Researchers from the University of Texas
found that it would be extremely easy for someone who has only a little
information about a person in the database to reidentify that person. 152
Anyone seeking to reidentify another person in a dataset would need to
know outside information about that person, such as the movies that
person rated, but such outside information may not be so difficult to
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find. 153 Ohm warns that in a world "awash in data about people," it is
"naive to assume that the adversary will be unable to find the particular
piece of data needed to unlock anonymized data." 154 Further, health
information, even if subject to the anonymization standards under
HIPAA, may be especially vulnerable; the eighteen identifiers that
must be suppressed for data to be DHI under the safe harbor standard
do not include other identifiers that could be used to reidentify a
dataset, including hospital name, diagnosis, year of visit, patient's age,
and the first three digits of the ZIP code. 155 These bits of information
could be used to reidentify datasets that have been supposedly
anonymized and qualify as DHI under HIPAA.156
The information transmitted by a Proteus digital pill may be
even more susceptible to re-identification. Sensors capture a wide
variety of data that can paint a detailed portrait of an individual,
rendering each individual in a sensor-based dataset unique. 15 7 This
makes sensor datasets highly sparse, meaning that individuals in the
dataset can be separated from the other individuals using only a few
attributes. 15 8 Sparse datasets are extremely difficult to anonymize. 159
To demonstrate this difficulty, MIT researchers discovered that by
locating individual users in a dataset within several hundred yards of
a cell-phone transmitter over the course of an hour on four occasions in
one year, they could identify 95% of the users in the dataset. 160 The
dataset contained anonymized data created by location-oriented
sensors on 1.5 million cell phone users in Europe over fifteen months. 161
These demonstrations of the ease of re-identification of
anonymized datasets should impress upon regulators and lawmakers
that laws and regulations that seek to protect privacy by requiring
anonymization, such as HIPAA's Privacy Rule, are inadequate,
especially as they concern sensor technologies like Proteus's digital pill.
Some regulators, such as the FTC, have sought to redefine information
along a spectrum of identifiability, rather than simply grouping
information into two categories: personally identifiable and not
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personally identifiable information. 162 Along a spectrum of this sort,
non-identifiable information would not be regulated.1 63 Information
that clearly identifies individuals would be heavily regulated, similar
to PHI under the HIPAA Privacy Rule, and potentially identifiable
information would be subject to less stringent limits on use and
disclosure. 1 6 4 The FTC listed three standards that, if met, would render
data outside the scope of the FTC's regulation: the dataset is not
reasonably identifiable, the company that owns the dataset commits not
to reidentify the data, and the company requires downstream users of
the data to commit not to reidentify the data.1 65
Some still find this approach inadequate; they argue that
determining whether data are reasonably identifiable will be
impossible.1 66 As Ohm puts it, "No matter how effectively regulators
follow the latest re-identification research, folding newly identified data
fields into new laws and regulations, researchers will always find more
data field types they have not yet covered."16 7 This may be particularly
true for sparse datasets generated by sensors like the Proteus digital
pill.168 It is impossible to know the kinds of information that new
technologies may be able to pull from human bodies in the coming years.
Due to the threat of re-identification, all of the information in these
datasets may need to be termed personally identifiable information, but
current laws and regulations will only protect certain types of
information. 169
C. The Incompatibility of Notice & Consent and the Digital Pill
In addition to relying on anonymization, policymakers have
embraced notice and choice as their principal method for regulating the
Internet.1 70 Notice and choice is essentially consumer consent in the
context of the Internet in which a firm provides information to the
consumer, usually in the form of a privacy policy, and then allows the
consumer to either accept or reject its services.171 With devices like the
162.
Peppet, supra note 1, at 132-33 (citing FED. TRADE COMM'N, PROTECTING CONSUMER
PRIVACY IN AN ERA OF RAPID CHANGE: RECOMMENDATIONS FOR BUSINESSES AND POLICYMAKERS
22 (2012)).
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digital pill, this approach to informing consumers about and gaining
their agreement to a company's information gathering processes is
highly problematic. First, logistically, there is no way to display a
privacy notice on a digital pill containing a sensor.1 7 2 Companies
providing devices, including wearables like the Fitbit, have had to find
other methods of presenting a privacy policy to their consumers for
acceptance, such as including a policy in the box the device comes in,
having the policy on the company website, and conveying the policy via
a mobile application associated with the device. 173
Even when companies can pull together a privacy policy and
offer it to consumers in a medium separate from the data-collecting
device, privacy policies are essentially complicated legal documents,
and therefore often cannot accurately and understandably describe
what information the device is collecting and how the company is using
that information. 174 When companies offer privacy policies via mobile
applications, they often apply only to the use of the app and therefore
run the risk of failing to provide adequate information about the
separate sensor device. 175 Further, it seems that technology may have
outgrown the concept of a privacy policy as the vast amount of data that
devices such as the digital pill are able to collect renders drafting a
sufficiently descriptive privacy policy almost impossible.1 7 6 There are
many possible misuses that consumers will not be able to read about in
a privacy policy.1 77 Even the Obama administration has acknowledged
that there will be instances in which the notice and consent framework
will no longer function adequately to protect consumers and allow them
to make meaningful choices about their personal information and how
it is shared. 178 The inadequacy of notice and consent is perhaps more
concerning than the lack of privacy regulation because it impedes
consumers' abilities to make educated decisions about what devices
they will use and how they will share their information. Even if a device
is unsecure or discloses consumers' personal information, the consumer
may decide that the benefits of the device outweigh these drawbacks,
but if consumers have no way of knowing what the risks are, the
consumers' autonomy to make meaningful choices disappears.
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D. Difficulty of Securing Sensor Data
Computer-security experts agree that smaller, sensor-based
devices are easier to hack than devices with a less compact form. 179
Among examples of devices that would be prone to data security
problems are the Fitbit fitness tracker, digital insulin pumps, and baby
monitors equipped with internet connection and cameras. A research
team from Florida International University showed that the Fitbit data
could be captured using simple tools from within fifteen feet.18 0 Another
security researcher proved that insulin pumps that communicated
wirelessly to a monitor used by diabetics to check insulin levels could
be easily accessed by hackers seeking to cause the monitor to display
inaccurate information that would lead the diabetic to administer the
wrong dose. 181
In addition, devices that are compact are said to have a "small
form factor," and while this may render devices more convenient to
consumers, it often also renders the device much harder to secure. 182 It
is difficult to include the processing power or the battery life needed to
support robust security measures like encryption devices with small
form factors. 183 Finally, devices like computers and smartphones boast
operating systems that can be updated remotely by software companies
to fix security problems after they have been released into the market
to protect against new threats and keep up with new security
developments. 18 4 Small sensor devices do not usually have such
operating systems and therefore cannot be updated to secure the
device.185

E. Potential Consequences of Privacy and Data Security Issues Facing
the Digital Pill
Even though the Proteus digital pill's data may be difficult to
secure, potentially weak data security may not be as great a problem as
it sounds. First, Proteus will have its own private incentives for
bolstering data security. 186 Both public and privately-held companies
likely suffer great financial losses when breaches occur, and firms
generally suffer more financially from identity fraud than do
179.
180.
181.
182.
183.
184.
185.
186.
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consumers.1 8 7 Second, there is evidence that the risk of harm to
consumers from data breaches is low. 188 A survey of consumers who
had received breach notifications found that only two percent of those
consumers had suffered any kind of identity fraud.1 89 Medical identity
theft is even more rare.1 90
Also, existing laws and regulations could address data security
issues. Where data security measures are deceptive or unfair, the FTC
Act applies and the FTC has been active in enforcing cases under both
prongs. 191 Many states have data breach notification laws, as well, and
even if Proteus were not required to adhere to rules about data security
measures and breach notification under HIPAA, the Recovery Act
would require Proteus, as a PHR vendor, to notify consumers and the
FTC in the event of a breach. 192
The privacy issues regarding the digital pill pose a greater
threat than the data security issues. First, it is unclear which privacy
laws will apply to the Proteus digital pill. If HIPAA does not apply to
the Proteus digital pill, Proteus could use and disclose its consumers'
information in a variety of ways that consumers would deem harmful.
Second, even if laws such as the HIPAA Privacy Rule do apply to the
Proteus digital pill, consumers' information and identities could still be
compromised due to re-identification. In either scenario, consumers'
personal information may fall into hands that the consumers would not
want their information falling into and that may use the information in
ways that would be harmful to consumers.
Medical information is unique in that it is both highly personal
For example, medical
to patients and valuable to businesses.1 9 3
information companies use pharmacy data to track drug prescriptions
and provide pharmaceutical companies and financial analysts with
information about pharmaceutical demand. 194 Employers also have an
interest in gleaning medical data about their current and potential
employees that they can use to make personnel decisions, and they
could easily turn to a company like Proteus for those data.19 s Data from
sensors such as the Proteus digital pill could also be used by insurers to
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set insurance premiums, lenders to assess creditworthiness, and
retailers to price discriminate. 196 The Proteus digital pill tracks general
health statistics about the patient taking the pill as well as whether
that patient, who presumably has a chronic disease, is taking her
medication as prescribed.19 7 This could be valuable to parties making
decisions about that patient.1 9 8 As Juliana Bell points out, "[t]he
disclosure of medical information, whether inadvertent or not, can lead
to embarrassment, ostracism, job loss, difficulty obtaining health
insurance, and health care fraud." 199 Equally important is the harm
that lack of privacy may cause to a consumer's notions of personal
liberty and autonomy. 200
These privacy and data security issues could lead to the inability
of drug companies to provide products such as the ingestible sensor due
to legal uncertainty or precautionary overregulation. 201 Policymakers,
anticipating harms that could result from the gaps in privacy law, the
inadequacy of data anonymization, and the potential weakness of data
security measures, may be moved to enact laws and regulations that
preemptively ban certain uses of data from the Proteus digital pill or
require Proteus to seek certain permissions. 202 Such measures could
prevent more benefit than harm. 203 The Proteus digital pill and other
ingestible sensors have the potential to significantly improve the
welfare of individuals and society by improving health outcomes for
chronically ill patients and reducing health care costs. 2 0 4 These
improvements may never be realized, though, if unnecessarily strict
regulations are imposed on these new technologies. 2 0 5 Such regulations
tend to reduce the ability of companies to produce new products,
maximize the quality of these projects, and provide these products at a
reasonable price. 206 Rather than predicting all possible worst-case
scenarios and imposing precautionary restraints to prevent these
scenarios from occurring, policymakers should utilize such
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precautionary regulations only when an immediate and extreme threat
to privacy and security has been clearly established. 207

III. SOLUTION
It is clear that a balance must be struck to mitigate between the
risk of overregulation that could destroy the benefits offered by digital
pills and the privacy risks that this technology presents to consumers.
Some have suggested that where the privacy and security risks posed
by a technology are great and the ability of consumers to adequately
gain notice and give consent to the information practices of a company
are diminished by incompatibility with the traditional privacy policy
paradigm, the regulatory response should be to impose "use
constraints." 208 Rushing to enact legislation or regulations that limit
how third parties can use private data should not be the answer,
though. Such regulation would bypass consent and impose restrictions
on the ways that companies and the third parties with whom they share
data can utilize information. 209 Although constraints on some uses may
eventually provide a solution to the privacy and data security issues
posed by ingestible sensors, use constraints should only be imposed
after a thorough cost-benefit analysis has been undertaken to examine
the potential benefits of the information extracted from the digital pill
against the risks of use of this information, and such analysis could take
years.
Although there is a lack of clarity as to what privacy laws will
apply to digital pills, there is evidence that risks, such as identity fraud,
are low. 2 1 0 If the risks are low and the consequences are mild, the cost
of overregulation may be too high to justify use constraints. People in
today's society readily accept the loss of their privacy in exchange for
efficiency, convenience, and small price discounts. The digital pill has
the potential to provide vast benefits to doctors and patients alike and
to alleviate the astronomical cost of health care. Caution must be taken
before regulating such technology out of existence.
Until an accurate analysis of the costs and benefits associated
with the information that can be gleaned from ingestible sensors by
companies like Proteus is conducted, it is clear that some precaution
must be taken to afford consumers an adequate level of protection.
207.
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Because of the uncertainty as to what laws apply to the digital pill, the
most pertinent risk to consumers using such technology is that they will
not be able to understand or control what information Proteus is
collecting and how that information is being used. With this in mind,
the precautions that should be put in place must improve upon the
notice and consent model. One potential improvement would be to
adapt a more rigorous method of affording patients a meaningful choice
by utilizing informed consent.
Before any physician treats a patient, that physician must
obtain informed consent. 211 According to the doctrine of informed
consent, when physicians make a treatment recommendation, they
must disclose to patients the risks and benefits of the proposed
treatment, as well as any realistic, available, alternative treatments or
no treatment at all, before it can be said that the patient has given his
or her informed consent to treatment. 212 Doctors prescribing the digital
pill could be required to inform patients about the privacy and data
security risks inherent in the pill.
They would describe what
information is being collected and list the types of third parties to whom
that information is being sent. The consumer would then be allowed to
consider this information, and if she chooses to fill the prescription for
the pill, then she would be manifesting her consent.
Using the framework of informed consent in the context of
digital pills has many advantages. First, unlike providing a privacy
policy for the consumer to read when the consumer opens the mobile
application associated with the pill, informed consent allows the
consumer to consider privacy concerns when she is still talking to her
doctor, she has not yet made the decision as to whether to take the
digital pill, and importantly, she has not yet paid for the pill. This
affords the consumer greater control and more opportunity to decline.
Second, when a consumer swipes through a privacy policy on an app for
a product that she has already purchased, she is probably less likely to
pay attention to the terms than if she is speaking to someone trusted,
like a doctor, who is explaining those terms.
There are some reasons this approach may not work. First, it
may be difficult for a doctor to verbally convey information that is
difficult to convey even using a written document. Doctors may also
balk at the suggestion that they take the time to explain the privacy
costs and benefits to patients. There may even be suggestions that if
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physicians convey this information, they could be sued by patients
whose privacy is later compromised.
On the other hand, doctors will be willing to take the extra time
to offer this information to their patients because of the immense
benefits they stand to gain from understanding the medication
adherence habits of their patients. There are ways to simplify the
information that needs to be conveyed to patients deciding whether to
use a digital pill. What physicians tell their patients could be crafted
by Proteus and other future digital pill manufacturers so that
physicians are essentially rehearsing a script. This would make the
digital pill very similar to any other prescription medication that
requires physicians to lay out the risks and side effects before
prescribing to patients. The information could also be conveyed in a
video that patients watch in the doctor's office so that doctors do not
have to give up precious time.
Further, it is unlikely that doctors would be found liable in a
malpractice case for any privacy or data security-related harm that a
patient experienced from using a digital pill simply because they
informed the patient of these risks; doctors in this situation would likely
not be providing care that falls below the standard of care. Doctors can
also be protected by having patients sign waivers that release them
from liability regarding the privacy and data security risks of the digital

pill.
Finally, using an informed consent model will avoid damage to
consumers' notions of autonomy and liberty by giving them greater
choice, and it will sidestep the risk of privacy laws becoming too
paternalistic. 2 13 In the end, regulations that constrain specific uses may
be necessary, but by strengthening methods for obtaining consent and
granting consumers a meaningful choice while deciding whether use
constraints should be used and what uses should be constrained,
legislators and regulators can avoid being viewed as overprotective and
allow a potentially beneficial technology to develop.
IV. CONCLUSION
Ingestible sensors have great potential to provide benefits both
financial and health related. The risks of the digital pill with regard to
privacy and data security may lead some to cry for preemptive
regulation. Those who argue for regulation and legislation, such as use
constraints, should exercise caution, though, and truly examine the
implications of regulation and the desires of consumers. Rather than
immediately limiting information use, policymakers should focus on
213.
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improving the methods by which consumers can be educated and give

consent.
If they do so, they will encourage the development of
technology with great potential, and they will promote the values of
liberty and autonomy that Americans hold dear.
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